![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Department of Pharmacology and Experimental Therapeutics, Loyola University Chicago, Maywood, Illinois (A.R.M., L.I.B., K.E.S., K.L.B.); and Department of Medicine/Cardiovascular Institute, Loyola University Chicago, Maywood, Illinois (K.K.H., A.J.S., L.L.C.)
Pressor effects of the vasoconstrictor hormone arginine vasopressin (AVP), observed when systemic AVP concentrations are less than 100 pM, are important for the physiological maintenance of blood pressure, and they are also the basis for therapeutic use of vasopressin to restore blood pressure in hypotensive patients. However, the mechanisms by which circulating AVP induces arterial constriction are unclear. We examined the novel hypothesis that KCNQ potassium channels mediate the physiological vasoconstrictor actions of AVP. Reverse transcriptase polymerase chain reaction revealed expression of KCNQ1, KCNQ4, and KCNQ5 in rat mesenteric artery smooth muscle cells (MASMCs). Whole-cell perforated patch recordings of voltage-sensitive K+ (Kv) currents in freshly isolated MASMCs revealed 1,3-dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2H-indol-2-one (linopirdine)- and 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone (XE-991)-sensitive KCNQ currents that were electrophysiologically and pharmacologically distinct from other Kv currents. Suppression of KCNQ currents by AVP (100 pM) was associated with significant membrane depolarization, and it was abolished by the protein kinase C (PKC) inhibitor calphostin C (250 nM). The KCNQ channel blocker linopirdine (10 µM) inhibited KCNQ currents in MASMCs, and it induced constriction of isolated rat mesenteric arteries. The vasoconstrictor responses were not additive when combined with 30 pM AVP, and they were prevented by the L-type Ca2+ channel blocker verapamil. Ethyl-N-[2-amino-6-(4-fluorophenylmethylamino)pyridin-3-yl] carbamic acid (flupirtine) significantly enhanced KCNQ currents, and it reversed constrictor responses to 30 pM AVP. In vivo, i.v. administration of linopirdine induced a dose-dependent increase in mesenteric artery resistance and blood pressure, whereas flupirtine had the opposite effects. We conclude that physiological concentrations of AVP induce mesenteric artery constriction via PKC-dependent suppression of KCNQ currents and L-type Ca2+ channel activation in MASMCs.
Address correspondence to: Dr. Kenneth L. Byron, Loyola University Medical Center, 2160 S. First Ave., Maywood, IL 60153. E-mail: kbyron{at}lumc.edu
This article has been cited by other articles:
|
|
 |
|
  T. A. Jepps, I. A. Greenwood, J. D. Moffatt, K. M. Sanders, and S. Ohya Molecular and functional characterization of Kv7 K+ channel in murine gastrointestinal smooth muscles Am J Physiol Gastrointest Liver Physiol, July 1, 2009; 297(1): G107 - G115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Joshi, V. Sedivy, D. Hodyc, J. Herget, and A. M. Gurney KCNQ Modulators Reveal a Key Role for KCNQ Potassium Channels in Regulating the Tone of Rat Pulmonary Artery Smooth Muscle J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 368 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Moreno-Dominguez, P. Cidad, E. Miguel-Velado, J. R. Lopez-Lopez, and M. T. Perez-Garcia De novo expression of Kv6.3 contributes to changes in vascular smooth muscle cell excitability in a hypertensive mice strain J. Physiol., February 1, 2009; 587(3): 625 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Mackie and K. L. Byron Cardiovascular KCNQ (Kv7) Potassium Channels: Physiological Regulators and New Targets for Therapeutic Intervention Mol. Pharmacol., November 1, 2008; 74(5): 1171 - 1179. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
